Lilly's Weight-Loss Pill Outsells Wegovy By Volume, Not Revenue
Foundayo is growing, Wegovy is enormous, and the cheap starter dose is turning a miracle-drug boom into a margin argument.
The news. The narrative. The timeline.
Foundayo is growing, Wegovy is enormous, and the cheap starter dose is turning a miracle-drug boom into a margin argument.
Measles, CDC vaccine language, and GLP-1 affordability are three versions of one problem, medicine asking people to trust systems they cannot audit.
Australia's import-permit regime shows that AI biosecurity is not only a model question, it is a border-control question.
Peter Raven's achievement was not only scientific stature, it was making a botanical garden behave like a civic institution with a global conscience.
Day 15 after the National Science Board firings leaves NSF with no board, no confirmed director, and no court filing to force an answer.
The NICE appeals move the Alzheimer's drug fight from miracle-versus-cost into the economics of carers, infusion time, and unpaid work.
The Pineland Road Fire is no longer just a burn map but a roads, smoke, timber, bees, and household-normality story.
Lake Powell's rescue now means one reservoir loses water, another keeps turbines alive, and households inherit the power risk.
The equatorial Pacific just printed its warmest April on record, giving climate readers a front page not built around war.
Utah's 638-case measles outbreak is now a November elimination-status story and a vaccine-trust story at once.
Idaho's unresolved H5N1 vector question depends on the milk-testing machinery that decides what investigators can see.
The CDC autism page is not only a wording fight when a Science experiment can measure lower vaccine intent.
Braunwald's AHA memorial page makes his legacy a funding and mentorship program, not only a great-man obituary.
The holiday is over, but the tequila and sovereignty receipts are still the better story than another margarita map.